Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430661 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
A Phase 1 study, sponsored by Viatris Innovation.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT03430661 is a Phase 1 study that has completed, run by Viatris Innovation. The registered enrollment target is 77 participants.
The verdict
NCT03430661, a Phase 1 study, has completed, sponsored by Viatris Innovation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female subjects
Interventions
- DRUG Placebo
- DRUG Clopidogrel
- DRUG Prasugrel
- DRUG Ticagrelor
- DRUG ACT-246475
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2019-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03430661
The ClinicalTrials.gov registry entry for NCT03430661 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viatris Innovation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03430661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03430661 about?
NCT03430661 is a clinical study titled "A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects". The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female subjects
What is the current status of trial NCT03430661?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2018-01-24. Estimated completion is 2019-05-29.
What interventions are being tested in trial NCT03430661?
The interventions under investigation include: Placebo (DRUG), Clopidogrel (DRUG), Prasugrel (DRUG), Ticagrelor (DRUG), ACT-246475 (DRUG).
Who is sponsoring clinical trial NCT03430661?
This trial is sponsored by Viatris Innovation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.